NCT05068076View on ClinicalTrials.gov

Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 16, 2021

Study Completion Date

December 16, 2021

Conditions

Hepatocellular CarcinomaMicrowave Ablation

Interventions

DRUG

Perfluorobutane

Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences, New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT05068076 - Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC | Biotech Hunter | Biotech Hunter